drugset / Trial / NCT06453135
Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to determine whether a single dose of eculizumab can effectively prevent antibody-mediated rejection in recipients undergoing living donor kidney transplantation with a different ABO blood group type than their donors
Timeline
- Start
- 2024-07
- Primary completion
- 2025-07
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eculizumab | Monoclonal antibody | 600 mg | — |
| Subject | Eculizumab | Monoclonal antibody | 900 mg | — |
Indications
No indication recorded.